Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with an increase in health span. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, a mitochondrial dysfunction for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. It has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Metrics to compare | GENF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGENFPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.8x | −6.4x | −0.5x | |
PEG Ratio | −0.07 | −0.04 | 0.00 | |
Price/Book | −7.1x | 4.8x | 2.6x | |
Price / LTM Sales | - | 13.4x | 3.3x | |
Upside (Analyst Target) | - | 78.5% | 42.8% | |
Fair Value Upside | Unlock | −14.5% | 6.5% | Unlock |